Consumers are on board, with an estimated 26% of U.S. adults planning to take a weight loss drug in 2025, according to ...

Stanford Medicine researchers have identified a naturally occurring molecule that mimics the appetite-suppressing effects of ...

The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET ...

According to Halozyme, the new version of Keytruda infringes on its patents, the report said. USAID cuts put tuberculosis response in peril, WHO says The Trump administration's decision to pause U.S.

Elsewhere in the obesity space — Amgen has initiated Phase 3 trials of its obesity drug MariTide, one in overweight and obese ...

A naturally occurring molecule identified by Stanford Medicine researchers appears similar to semaglutide—also known as ...

A detailed review of a 6-month clinical trial further reinforces strong experimental evidence that a ketogenic diet may offer ...

Merck KGaA on Thursday forecast currency-adjusted operating earnings growth of up to 8%, helped by demand for semiconductor ...

We know that weight loss drugs have been big winners for the companies that produce them. And now, biotech stock Amgen (AMGN) ...

Merck's injected version of its blockbuster cancer drug Keytruda could face a potential patent challenge from biotech ...

MariTide is a monthly injection that investors hope could compete against existing weight loss drugs from Novo Nordisk and ...

Amgen (NASDAQ:AMGN) stock in focus as company starts Phase 3 trials for obesity drug MariTide, aiming to challenge Eli Lilly ...